Biomedical Translation Bridge Program

Banner Image

Round 3 Rapid COVID-19 Response Funding Opportunity Now Closed

In this specific COVID-19 call, the BTB Program can provide up to $1 million to support eligible organisations develop medical devices, diagnostics, prophylactic or therapeutic approaches that will achieve an impact on the global response to the pandemic in less than 12-months.

Expressions of interest have now closed. The funding from this round will support Australian small and medium enterprises, medical research institutes and universities conducting COVID-19 related research projects. Applicants will be required to provide one-to-one matching funding in the form of cash to be eligible.

COVID-19 CALL GUIDELINES COVID-19 CALL FAQS


About the BTB Program

The Biomedical Translation Bridge program is an initiative of the Medical Research Future Fund, providing up to $1 million in matching funding to nurture the translation of new therapies, technologies and medical devices through to the proof of concept stage.

The BTB program is operated by MTPConnect, in partnership with BioCurate (University of Melbourne and Monash University), UniQuest (University of Queensland through its drug discovery initiative QEDDI), the Medical Device Partnering Program (MDPP, led by Flinders University), and the Bridge and BridgeTech programs (Queensland University of Technology); all pre-eminent organisations engaged in the translation and commercialisation of health and medical research.

Contact Director of BTB Lauren Kelly for more information.


Round 2 is Closed

Round 2 is under assessment. Watch this space for awardee announcements.

  BTB GUIDELINES FAQS INFORMATION SLIDE DECK

EOI templates for medical device or therapeutic projects can be downloaded below. For combination projects, applicants will be required to answer the 'Project Specific Questions' captured in both forms. 

MEDICAL DEVICE EOI TEMPLATE THERAPEUTIC EOI TEMPLATE


Round 1 Funded Projects

  • AdAlta Limited, Victoria, is developing clinical imaging of the cell surface receptor CXCR4 in idiopathic pulmonary fibrosis (IPF) patients. IPF is a progressive lung disease consisting of recurring inflammation and damage that causes the lung to stiffen, making it hard to breathe.
  • Australian National University, Australian Capital Territory, is developing rapid and objective eye and brain testing for better management of ophthalmic and neurological diseases.
  • DBS Technologies Pty Ltd, Victoria, is developing an innovative device providing adaptive deep brain stimulation for people with Parkinson’s disease.
  • MecRx Pty Ltd, Victoria, is developing novel, small molecule therapeutics for the treatment of lung cancer.
  • Noisy Guts Pty Ltd, Western Australia, has developed a non-invasive acoustic belt that uses artificial intelligence to decode gut noises to accurately diagnose and monitor common gut disorders such as Irritable Bowel Syndrome
  • SpeeDx Pty Ltd, New South Wales, is seeking to commercialise its ResistancePlus® MABSC/MAC test, a rapid in vitro diagnostic tool to accurately and quickly identify bacterial infections related to Cystic Fibrosis, while using gene markers to predict antibiotic susceptibility or resistance.
  • University of Melbourne’s Melbourne Dental School, Victoria, is progressing a novel dental implant to commercialisation.
  • Vast Bioscience, Queensland, is developing 3D small molecule sodium channel inhibitors for the treatment of postsurgical pain.

Related Podcasts:

  • Listen to our podcast for our live R1 Information Session at the Victorian Comprehensive Cancer Centre (VCCC) in Melbourne.
  • Listen to our podcast for our live R2 Information Session at the Melbourne Convention and Exhibition Centre.